Revolution Medicines has established a deep pipeline of programs targeting critical signaling nodes within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways.

 
 
fpo
 
 
 

RMC-4630, a potent and selective inhibitor of SHP2, is currently in a multi-cohort Phase 1/2 clinical program for a range of tumor types.

Read more

We believe our mutant-selective RAS inhibitors are the first potent, selective, cell-active inhibitors of the active, GTP-bound forms of RAS, or RAS(ON).

Read more

We believe that inhibition of SOS1 may represent a viable approach for targeting RAS-driven tumors.

Read More

RMC-5552, a potent and selective inhibitor of mTORC1, is designed to prevent inactivation of the tumor suppressive properties of the 4EBP1 protein.

Read More